1. Taiwan, Province of China Stocks

  2. •

    Healthcare

  3. •

    Biotechnology
Mycenax Biotech Inc.

Mycenax Biotech Inc.

4726.TWO
Mycenax Biotech Inc.TW flagTaipei Exchange
26.00
TWD
-0.45
- -
5.38BMarket Cap

Total Valuation

Mycenax Biotech Inc. carries a market capitalization of 5.38B, placing it among publicly traded companies globally. Its enterprise value stands at 7.39B, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

Market Cap5.38B
Enterprise Value7.39B

Share Statistics

Mycenax Biotech Inc. currently has 207.23M shares outstanding.

Shares Outstanding207.23M
Owned by Insiders (%)N/A
Owned by Institutions (%)N/A

Valuation Ratios

The price-to-sales ratio is 8.84, and the price-to-book ratio stands at 4.27.

PE RatioN/A
PS Ratio8.84
PB Ratio4.27
P/TBV Ratio4.20
P/FCF Ratio91.06
P/OCF Ratio-240.13

Enterprise Valuation

EV / Sales9.98
EV / EBITDAN/A
EV / EBITN/A
EV / FCF70.29

Financial Position

Mycenax Biotech Inc. maintains a current ratio of 0.70, meaning it holds 0.7x the short-term assets needed to cover near-term liabilities. The debt-to-equity ratio is 67.03, indicating elevated leverage, while an interest coverage ratio of -12.04 demonstrates limited ability to service its debt obligations.

Current Ratio0.70
Quick Ratio0.20
Debt / Equity67.03
Debt / EBITDA-2.64
Interest Coverage-12.04

Financial Efficiency

Return on Equity (ROE)-28.62
Return on Assets (ROA)-13.53
Return on Invested Capital (ROIC)N/A
Return on Capital Employed (ROCE)N/A
Revenue Per EmployeeN/A
Employee CountN/A
Inventory Turnover9.32

Taxes

Income Tax-5.48M
Effective Tax RateN/A

Stock Price Statistics

Mycenax Biotech Inc.'s stock has declined approximately -31.57895% over the past 52 weeks. The 50-day moving average sits at 27.07, while the 200-day moving average is 31.59.

Beta (5Y)N/A
52-Week Price Change-31.57895%
50-Day Moving Average27.07
200-Day Moving Average31.59
Average Volume (20 Days)N/A

Income Statement

Over the trailing twelve months, Mycenax Biotech Inc. generated 740.24M in revenue and converted that into -448.63M in net income, yielding earnings per share of -2.17. EBITDA reached -405.39M, while operating income came in at -405.39M.

Revenue740.24M
Gross Profit-181.41M
Operating Income-405.39M
Pretax Income-454.11M
Net Income-448.63M
EBITDA-405.39M
EBIT-405.39M
Earnings Per Share (EPS)-2.17

Balance Sheet

Mycenax Biotech Inc. holds 225.75M in cash and equivalents against 1.07B in total debt, resulting in a net debt position of 685.68M. Total book value stands at 1.53B, with working capital of -330.04M providing operational flexibility.

Cash & Cash Equivalents225.75M
Total Debt1.07B
Net Debt685.68M
Equity (Book Value)1.53B
Book Value Per Share7.40
Working Capital-330.04M

Cash Flow

Mycenax Biotech Inc. produced -27.24M in operating cash flow over the past twelve months. After subtracting -99.08M in capital expenditures, free cash flow totaled -126.32M - equivalent to -0.61 per share.

Operating Cash Flow-27.24M
Capital Expenditures-99.08M
Free Cash Flow-126.32M
FCF Per Share-0.61

Margins

Mycenax Biotech Inc. operates with a gross margin of -24.51, reflecting its pricing power and cost economics. The operating margin of -54.76 and net profit margin of -60.61 provide insight into operational efficiency.

Gross Margin-24.51
Operating Margin-54.76
Pretax Margin-61.35
Profit Margin-60.61
EBITDA Margin-54.76

Dividends & Yields

Dividend Per ShareN/A
Dividend YieldN/A
Payout RatioN/A
Shareholder Yield-1.45
FCF Yield1.10

Stock Splits

Mycenax Biotech Inc.'s most recent stock split took place on December 17, 2012 with a 1000:1163 split ratio.

Last Split Date12/17/2012
Split Ratio1000:1163

Scores

Mycenax Biotech Inc. posts an Altman Z-Score of 1.82, near the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.

Altman Z-Score1.82